Digital health firm Arcensus appoints new CEO

Digital health and diagnostics firm Arcensus has appointed its founder, Professor Dr Arndt Rolfs, as CEO.

Professor Rolfs succeeds Michael Schlenk, who will remain an active member of its supervisory board.

Rolfs is a multi-entrepreneur in biotech and former CEO of several innovative biotech companies, including Nasdaq-listed company CENTOGENE.

Mr Schlenk wished the new CEO every success, saying: “There is no doubt that this year will bring great progress for Arcensus after building the company so successfully in a record time. I look forward to supporting the shaping of the business model as a member of the supervisory board.”

A company statement said: “Professor Rolfs is an experienced biotech entrepreneur who knows the necessities and challenges of the healthcare industry very well.

“Under his leadership, Arcensus will disrupt the genetic diagnostics market through the rapid expansion of its global genomic service and develop new concepts based on genomic knowledge generated worldwide. Arcensus’ genomic data already has a diagnostic yield of about 80 per cent in all genetically suspect patients.

Professor Rolfs said: “Our expertise in the high-quality interpretation of whole genome DNA sequencing data reflects the next revolution in modern medicine. Our global genomic knowledge will help pharma partners accelerate the development of new drugs, especially for rare diseases.”

Arcensus is a digital healthcare and diagnostics company that “empowers people to take control of their health“, providing services based on whole genome sequencing.

Arcensus analyses the complete genetic information in human DNA and identifies the predispositions as well as reasons for unclear symptoms with the help of cutting-edge technology including artificial intelligence.

It has offices in Rostock and Berlin in Germany, and New Jersey, US. It has a cross-functional team of genetic experts, medical doctors, and data scientists.